Benzinga
Benzinga
Benzinga
mercredi, septembre 30

Elicio Therapeutics Inc

ELTXNASDAQ
Trade with Public
Trade with Public
$1.84
-0.01-0.54%
À la clôture: Sep 29, 5:00 PM EST
$1.84
N/A
Après les heures: 4:00 PM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

Elicio Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Elicio Therapeutics (ELTX).

Price Target Range — 10 Quarters

Analyst Consensus — 5 Analysts

4Buy
1Hold
Consensus RatingBuy# Analysts5Avg. Consensus PT$15Upside to Avg. PT+706.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →
DateFirmAnalystActionRating ChangePrice Target
Sep 24, 2026B. Riley SecuritiesMayank MamtaniPT CutBuy$27→$8
Aug 18, 2026HC Wainwright & Co.Robert BurnsMaintainedBuy$23
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
B. Riley Securities Maintains Buy on Elicio Therapeutics, Lowers Price Target to $8

B. Riley Securities analyst Mayank Mamtani maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and lowers the price target from $27 to $8.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $23 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Elicio Therapeutics (NASDAQ:ELTX) with a Buy and maintains $23 price target.
Benzinga Newsdesk

PRO
Ladenburg Thalmann Assumes Elicio Therapeutics at Buy, Announces Price Target of $12

Ladenburg Thalmann analyst Kevin DeGeeter assumes Elicio Therapeutics (NASDAQ:ELTX) with a Buy rating and announces Price Target of $12.
Benzinga Newsdesk

PRO
Jones Trading Downgrades Elicio Therapeutics to Hold

Jones Trading analyst Boris Peaker downgrades Elicio Therapeutics (NASDAQ:ELTX) from Buy to Hold.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Raises Price Target to $23

HC Wainwright & Co. analyst Robert Burns maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and raises the price target from $17 to $23.
Benzinga Newsdesk

PRO
B. Riley Securities Initiates Coverage On Elicio Therapeutics with Buy Rating, Announces Price Target of $27

B. Riley Securities analyst Mayank Mamtani initiates coverage on Elicio Therapeutics (NASDAQ:ELTX) with a Buy rating and announces Price Target of $27.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved